EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.
EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.
2018 Korea CPHI, C30
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
1.
Valbenazine，CAS#1025504-45-3, HNMR, HPLC 99%+, LCMS, COA, MSDS and ROS, more than 32KG in stock, pls check:
Name:Valbenazine
CAS#: 1025504-45-3
Formula: C24H38N2O4
Exact Mass: 418.2832
Molecular Weight: 418.578
Elemental Analysis: C, 68.87; H, 9.15; N, 6.69; O, 15.29
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
2.
Valbenazine Intermediates:
1. Valbenazine Intermediate:(2-Acetyl-4-Methylpentyl)trimethylammonium Iodide,
1. Valbenazine Intermediate:(2-Acetyl-4-Methylpentyl)trimethylammonium Iodide,
Cas#1069-62-1,
We have more than 46kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
2. Valbenazine Intermediate:6,7-Dimethoxy-3,4-dihydroisoquinoline
Cas#3382-18-1
We have more than 53kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
3. Valbenazine Intermediate:3-isobutyl-9,10-dimethoxy-3,4,6,7-tetrahydro-1H-pyrido[2,1-a]isoquinolin-2(11bH)-one
Cas#718635-93-9
We have more than 47kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
4. Valbenazine Intermediate:2H-Benzo[a]quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-, (3R,11bR)-
Cas#1026016-83-0
We have more than 35kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
5. Valbenazine Intermediate:[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol
Cas#85081-18-1
We have more than 54kg in stock, assay 99% in GMP plant, C-GMP standard,
now COA, NMR, HPLC, MS is ok.
REFERENCES:
1: O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7. doi: 10.1002/mds.26330. Epub 2015 Sep 8. PubMed PMID: 26346941; PubMed Central PMCID: PMC5049616.
2: Barquero N. Valbenazine for the treatment of tardive dyskinesia. Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977. Review. PubMed PMID: 28276538.
3: Müller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015 Jun;24(6):737-42. doi: 10.1517/13543784.2015.1029573. Epub 2015 Mar 25. PubMed PMID: 25809133.
4: Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. doi: 10.1124/jpet.116.239160. Epub 2017 Apr 12. PubMed PMID: 28404690.
5: Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016 Dec;21(S1):13-24. doi: 10.1017/S1092852916000730. Review. PubMed PMID: 28044943.
6: Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec;17(18):2461-2470. Review. PubMed PMID: 27819145.
7: Citrome L. Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next? CNS Spectr. 2016 Dec;21(S1):1-12. doi: 10.1017/S1092852916000729. Review. PubMed PMID: 28044942.
8: Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21. PubMed PMID: 28320223.
9: Garay RP, Citrome L, Samalin L, Liu CC, Thomsen MS, Correll CU, Hameg A, Llorca PM. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17(7):921-36. doi: 10.1517/14656566.2016.1149164. Epub 2016 Feb 19. Review. PubMed PMID: 26831200.
10: Kane JM, Correll CU, Liang GS, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):69-76. PubMed PMID: 28839342; PubMed Central PMCID: PMC5546553.
11: Freudenreich O, Remington G. Valbenazine for Tardive Dyskinesia. Clin Schizophr Relat Psychoses. Summer 2017;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717. Review. PubMed PMID: 28742396.
12: Correll CU, Josiassen RC, Liang GS, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):53-60. PubMed PMID: 28839340; PubMed Central PMCID: PMC5546551.
13: Kim ES. Valbenazine: First Global Approval. Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Review. PubMed PMID: 28578484.
14: Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. N Engl J Med. 2017 Jun 29;376(26):2503-2506. doi: 10.1056/NEJMp1704898. Epub 2017 May 10. PubMed PMID: 28489481.
15: Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother. 2017 Aug;18(12):1279-1287. doi: 10.1080/14656566.2017.1353078. Epub 2017 Aug 2. PubMed PMID: 28699794.
16: Citrome L. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017 Jul;71(7). doi: 10.1111/ijcp.12964. Epub 2017 May 12. Review. PubMed PMID: 28497864.
17: Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):61-68. PubMed PMID: 28839341; PubMed Central PMCID: PMC5546552.
18: Witter DP, Holbert RC, Suryadevara U. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opin Pharmacother. 2017 Jul;18(10):965-972. doi: 10.1080/14656566.2017.1323874. Epub 2017 May 8. PubMed PMID: 28443349.
19: Valbenazine (Ingrezza) for tardive dyskinesia. Med Lett Drugs Ther. 2017 May 22;59(1521):83-84. PubMed PMID: 28520698.
20: Traynor K. Valbenazine approved for treatment of tardive dyskinesia. Am J Health Syst Pharm. 2017 May 15;74(10):628-629. doi: 10.2146/news170031. PubMed PMID: 28483934.
